{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:29:07Z","timestamp":1786980547115,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T00:00:00Z","timestamp":1477353600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Progressive Renal Research Projects of the Ministry of Health, Labor and Welfare, Japan"},{"name":"the Japan Kidney Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s10157-016-1340-2","type":"journal-article","created":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T09:49:34Z","timestamp":1477388974000},"page":"961-970","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome"],"prefix":"10.1007","volume":"21","author":[{"name":"The Refractory Nephrotic Syndrome Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1279-6400","authenticated-orcid":false,"given":"Takao","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Iwano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Mitarai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Yorioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashio","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Ogahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshie","family":"Sasatomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enyu","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Tomino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,25]]},"reference":[{"key":"1340_CR1","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/j.1523-1755.2004.00518.x","volume":"65","author":"H Shiiki","year":"2004","unstructured":"Shiiki H, Saito T, Nishitani Y, Mitarai T, Yorioka N, Yoshimura A, et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int. 2004;65:1400\u20137.","journal-title":"Kidney Int"},{"key":"1340_CR2","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1038\/kisup.2012.9","volume":"2","author":"DC Cattran","year":"2012","unstructured":"Cattran DC, Feehally J, Cook HT, et al. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2:S139\u2013274.","journal-title":"Kidney Int Suppl"},{"key":"1340_CR3","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/sj.ki.5002553","volume":"72","author":"DC Cattran","year":"2007","unstructured":"Cattran DC, Alexopoulos E, Heering P, Hoyer PF, Johnston A, Meyrier A, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int. 2007;72:1429\u201347.","journal-title":"Kidney Int"},{"key":"1340_CR4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1523-1755.2000.00168.x","volume":"58","author":"K Yoshioka","year":"2000","unstructured":"Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, et al. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int. 2000;58:317\u201324.","journal-title":"Kidney Int"},{"key":"1340_CR5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10157-004-0276-0","volume":"8","author":"T Shibasaki","year":"2004","unstructured":"Shibasaki T, Koyama A, Hishida A, Muso E, Osawa G, Yamabe H, et al. A randomized open-label comparative study of conventional therapy versus mizoribine onlay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey). Clin Exp Nephrol. 2004;8:117\u201326.","journal-title":"Clin Exp Nephrol."},{"key":"1340_CR6","doi-asserted-by":"crossref","first-page":"936","DOI":"10.3109\/0886022X.2013.808133","volume":"35","author":"Y Matsumoto","year":"2013","unstructured":"Matsumoto Y, Shimada Y, Nojima Y, Moriki T. Efficacy of mizoribine followed by low-dose prednisone in patients with idiopathic membranous nephropathy and nephrotic-range proteinuria. Ren Fail. 2013;35:936\u201341.","journal-title":"Ren Fail"},{"key":"1340_CR7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11255-014-0850-7","volume":"47","author":"T Ito","year":"2015","unstructured":"Ito T, Mochizuki K, Oka T, Hanada K, Tanabe K. Study of mizoribine therapy in elderly patients with membranous nephropathy: comparison with patients not receiving mizoribine. Int Urol Nephrol. 2015;47:131\u20135.","journal-title":"Int Urol Nephrol"},{"key":"1340_CR8","first-page":"3643","volume":"28","author":"K Sonda","year":"1996","unstructured":"Sonda K, Takahashi K, Tanabe K, Funchinoue S, Hayasaka Y, Kawaguchi H, et al. Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transplant Proc. 1996;28:3643\u20138.","journal-title":"Transplant Proc."},{"key":"1340_CR9","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1016\/0006-2952(83)90301-5","volume":"32","author":"H Koyama","year":"1983","unstructured":"Koyama H, Tsuji M. Genetic and biochemical studies on the activation and cytotoxic mechanism of bredinin, a potent inhibitor of purine biosynthesis in mammalian cells. Biochem Pharmacol. 1983;32:3547\u201353.","journal-title":"Biochem Pharmacol"},{"key":"1340_CR10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/cbf.290070308","volume":"7","author":"T Kusumi","year":"1989","unstructured":"Kusumi T, Tsuda M, Katsunuma T, Yamamura M. Dual inhibitory effect of bredinin. Cell Biochem Funct. 1989;7:201\u20134.","journal-title":"Cell Biochem Funct"},{"key":"1340_CR11","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1681\/ASN.2006070732","volume":"18","author":"A Nakajo","year":"2007","unstructured":"Nakajo A, Khoshnoodi J, Takenaka H, Hagiwara E, Watanabe T, Kawakami H, et al. Mizoribine corrects defective nephrin biogenesis by restoring intracellular energy balance. J Am Soc Nephrol. 2007;18:2554\u201364.","journal-title":"J Am Soc Nephrol"},{"key":"1340_CR12","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1093\/ndt\/gfl108","volume":"21","author":"Y Nishioka","year":"2006","unstructured":"Nishioka Y, Horita Y, Tadokoro M, Taura K, Suyama N, Miyazaki M, et al. Changing mizoribine administration from three divided doses to one single dose induced remission of relapsed membranous nephropathy. Nephrol Dial Transplant. 2006;21:2337\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"1340_CR13","doi-asserted-by":"crossref","unstructured":"Ichinose K1, Origuchi T, Kawashiri SY, Iwamoto N, Fujikawa K, Aramaki T, et al. Efficacy and safety of mizoribine by one single dose administration for patients with rheumatoid arthritis. Intern Med. 2010;49:2211\u20138.","DOI":"10.2169\/internalmedicine.49.3810"},{"key":"1340_CR14","unstructured":"Ehrenreich T, Churg J. Pathology of membranous nephropathy. In: Sommers SC, editor. The Pathology Annual no. 3. New York: Appleton-Century-Crofts; 1968;145\u2013186."},{"key":"1340_CR15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0378-4347(00)80663-5","volume":"432","author":"H Hosotsubo","year":"1988","unstructured":"Hosotsubo H, Takahara S, Taenaka N. Simplified high-performance liquid chromatographic method for determination of mizoribine in human serum. J Chromatogr. 1988;432:340\u20135.","journal-title":"J Chromatogr"},{"key":"1340_CR16","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1248\/bpb.29.2460","volume":"29","author":"M Honda","year":"2006","unstructured":"Honda M, Itoh H, Suzuki T, Hashimoto Y. Population pharmacokinetics of higher-dose mizoribine in healthy male volunteers. Biol Pharm Bull. 2006;29:2460\u20134.","journal-title":"Biol Pharm Bull"},{"key":"1340_CR17","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s10157-011-0487-0","volume":"15","author":"K Ishida","year":"2011","unstructured":"Ishida K, Okamoto M, Ishibashi M, Hashimoto Y. Population pharmacokinetics of mizoribine in adult recipients of renal transplantation. Clin Exp Nephrol. 2011;15:900\u20136.","journal-title":"Clin Exp Nephrol"},{"key":"1340_CR18","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","volume":"59","author":"DC Cattran","year":"2001","unstructured":"Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int. 2001;59:1484\u201390.","journal-title":"Kidney Int"},{"key":"1340_CR19","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1093\/ndt\/gfl360","volume":"21","author":"E Alexopoulos","year":"2006","unstructured":"Alexopoulos E, Papagianni A, Tsamelashvili M, Leontsini M, Memmos D. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transplant. 2006;21:3127\u201332.","journal-title":"Nephrol Dial Transplant"},{"key":"1340_CR20","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1007\/s10157-013-0925-2","volume":"18","author":"T Saito","year":"2014","unstructured":"Saito T, Iwano M, Matsumoto K, Mitarai T, Yokoyama H, Yorioka N, et al. Significance of combined cyclosporine-prednisolone therapy and cyclosporine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome: a randomized controlled multicenter trial. Clin Exp Nephrol. 2014;18:784\u201394.","journal-title":"Clin Exp Nephrol"},{"key":"1340_CR21","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s10157-013-0780-1","volume":"17","author":"S Takahara","year":"2013","unstructured":"Takahara S, Takahashi K, Akiyama T, Uchida K, Tanabe K, Amada N, et al. Randomized comparative trial of mizoribine versus mycophenolate mofetil in combination with tacrolimus for living donor renal transplantation. Clin Exp Nephrol. 2013;17:899\u2013904.","journal-title":"Clin Exp Nephrol"},{"key":"1340_CR22","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.clinbiochem.2014.01.014","volume":"7","author":"S Xing","year":"2014","unstructured":"Xing S, Yang J, Zhang X, Zhou P. Comparative efficacy and safety of mizoribine with mycophenolate mofetil for Asian renal transplantation\u2013a meta-analysis. Clin Biochem. 2014;7:663\u20139.","journal-title":"Clin Biochem"},{"key":"1340_CR23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.5414\/CNP63417","volume":"63","author":"H Tanaka","year":"2005","unstructured":"Tanaka H, Tsugawa K, Nakahata T, Kudo M, Suzuki K, Ito E. Implication of the peak serum level of mizoribine for control of the serum anti-dsDNA antibody titer in patients with lupus nephritis. Clin Nephrol. 2005;63:417\u201322.","journal-title":"Clin Nephrol"},{"key":"1340_CR24","doi-asserted-by":"crossref","unstructured":"Nozu K, Iijima K, Kamioka I, Fujita T, Yoshiya K, Tanaka R. et al. High-dose mizoribine treatment for adolescents with systemic lupus erythematosus. Pediatr Int. 2006;48:152\u20137.","DOI":"10.1111\/j.1442-200X.2006.02178.x"},{"key":"1340_CR25","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00467-009-1341-4","volume":"25","author":"Y Tanaka","year":"2010","unstructured":"Tanaka Y, Yoshikawa N, Hattori S, Sasaki S, Ando T, Ikeda M, et al. Combination therapy with steroids and mizoribine in juvenile SLE: a randomized controlled trial. Pediatr Nephrol. 2010;25:877\u201382.","journal-title":"Pediatr Nephrol"},{"key":"1340_CR26","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.transproceed.2011.11.020","volume":"44","author":"N Nakamura","year":"2012","unstructured":"Nakamura N, Mikami H, Matsuoka H, Irie S, Abe Y, Sasatomi Y, et al. Experiences of high-dose mizoribine as antimetabolite immunosuppressants for kidney transplantation. Transplant Proc. 2012;44:150\u20133.","journal-title":"Transplant Proc."},{"key":"1340_CR27","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s10157-015-1209-9","volume":"20","author":"H Kaneda","year":"2015","unstructured":"Kaneda H, Shimizu M, Ohta K, Ushijima K, Gotoh Y, Satomura K, et al. Population pharmacokinetics of mizoribine in pediatric patients with kidney disease. Clin Exp Nephrol. 2016;20:757\u201363.","journal-title":"Clin Exp Nephrol"},{"key":"1340_CR28","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1742-7843.2009.00489.x","volume":"106","author":"T Naito","year":"2010","unstructured":"Naito T, Tokashiki S, Mino Y, Otsuka A, Ozono S, Kagawa Y, et al. Impact of concentrative nucleoside transporter 1 gene polymorphism on oral bioavailability of mizoribine in stable kidney transplant recipients. Basic Clin Pharmacol Toxicol. 2010;106:310\u20136.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1340_CR29","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2133\/dmpk.DMPK-11-NT-040","volume":"26","author":"M Fukao","year":"2011","unstructured":"Fukao M, Ishida K, Sakamoto T, Taguchi M, Matsukura H, Miyawaki T, et al. Effect of genetic polymorphisms of SLC28A1, ABCG2, and ABCC4 on bioavailability of mizoribine in healthy Japanese males. Drug Metab Pharmacokinet. 2011;26:538\u201343.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1340_CR30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2133\/dmpk.DMPK-12-NT-043","volume":"28","author":"K Ishida","year":"2013","unstructured":"Ishida K, Fukao M, Watanabe H, Taguchi M, Miyawaki T, Matsukura H, et al. Effect of salt intake on bioavailability of mizoribine in healthy Japanese males. Drug Metab Pharmacokinet. 2013;28:75\u201380.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1340_CR31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1006\/bbrc.2000.3104","volume":"274","author":"S Takahashi","year":"2000","unstructured":"Takahashi S, Wakui H, Gustafsson JA, Zilliacus J, Itoh H. Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein. Biochem Biophys Res Commun. 2000;274:87\u201392.","journal-title":"Biochem Biophys Res Commun."},{"key":"1340_CR32","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1007\/s00467-006-0120-8","volume":"21","author":"H Tanaka","year":"2006","unstructured":"Tanaka H, Tsugawa K, Suzuki K, Nakahata T, Ito E. Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis. Pediatr Nephrol. 2006;21:962\u20136.","journal-title":"Pediatr Nephrol"},{"key":"1340_CR33","doi-asserted-by":"crossref","first-page":"c73","DOI":"10.1159\/000151721","volume":"110","author":"H Tanaka","year":"2008","unstructured":"Tanaka H, Oki E, Tsuruga K, Sato N, Matsukura H, Matsunaga A, et al. Mizoribine treatment of young patients with severe lupus nephritis: a clinicopathologic study by the Tohoku Pediatric Study Group. Nephron Clin Pract. 2008;110:c73\u20139.","journal-title":"Nephron Clin Pract"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-016-1340-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-016-1340-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-016-1340-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T01:10:46Z","timestamp":1718845846000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-016-1340-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,25]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1340"],"URL":"https:\/\/doi.org\/10.1007\/s10157-016-1340-2","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,25]]}}}